| Checking Up on the Doctor Doctors readily dispense prescriptions and advice, but what do they do themselves? A number of surveys, polls and questionnaires provide some clues—and some surprises, writes Melinda Beck. online.wsj.com |
Employers Race for Retiree Funds Some employers worry a $5 billion federal fund created under the health care overhaul bill and intended to help offset the costs of providing health care for early retirees will be exhausted quickly. online.wsj.com |
WHO: Swine-Flu Pandemic Is Over Nearly 14 months after declaring a new H1N1 flu to be a pandemic, the World Health Organization said that it's over. online.wsj.com |
Martek Biosciences Beats Estimates on Surging Sales Zacks.com submits: Martek Biosciences Corporation’s (MATK) third-quarter fiscal 2010 earnings (excluding special items) of 38 cents per share surpassed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 11 cents. On a reported basis (including special items), the company earned 35 cents per share in the reported quarter as against 27 cents in the year-ago quarter. The higher earnings in the reported quarter were driven by a surge in sales. Sales in the quarter benefited from the purchase of Amerifit Brands in February this year coupled with a rise in nutritional ingredient sales. Complete Story » seekingalpha.com |
Zalicus: Ridiculously Cheap Jeremy Richards submits:CombinatoRx (formerly CRXX) recently changed its name to Zalicus (ZLCS) - a healthy positioned biopharmaceutical company with new and existing product developments. Zalicus is considerably undervalued. and should easily be trading double its current stock price. Zalicus discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinsons disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis (NVS) Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases.Complete Story » seekingalpha.com |